GlassScriptPhysician profile
Suzan S Pae
NPI 1811977580
$7,832.99
in general payments reported to CMS, 2019-2025
34 companies · $1,267 in 2025
The $1,267 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $772 · 2020: $401 · 2021: $756 · 2022: $850 · 2023: $1,051 · 2024: $2,737 · 2025: $1,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,912 · Consulting Fee: $2,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,911.83 |
| Consulting Fee | $2,142.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Consortium of Independent Immunology Clinics, LLC | $2,142.92 | 2024-2025 | |
| Genzyme Corporation | $1,987.17 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,051.30 | 2019-2025 | Fasenra, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $292.70 | 2020-2024 | Takhzyro, Eohilia, Hyqvia |
| Amgen INC. | $267.49 | 2021-2025 | Tezspire |
| Kaleo, INC. | $229.06 | 2019-2023 | Auvi-Q |
| Csl Behring | $215.70 | 2019-2023 | Hizentra |
| Glaxosmithkline, LLC. | $183.17 | 2019-2025 | Nucala |
| Novartis Pharmaceuticals Corporation | $181.86 | 2019-2025 | |
| Optinose US, INC. | $170.96 | 2019-2022 | |
| Abbvie INC. | $141.06 | 2021-2023 | |
| Octapharma USA, INC. | $97.10 | 2023-2024 | Octagam Immune Globulin (Human) |
| Hospira, INC. | $84.71 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $82.59 | 2019-2025 | Dupixent |
| Shire North American Group INC | $80.26 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.94 | 2019-2020 | |
| Horizon Therapeutics Plc | $63.61 | 2021 | |
| Genentech USA, INC. | $56.90 | 2021-2023 | Xolair |
| Biocryst US Sales Co., LLC | $51.05 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $50.34 | 2020-2023 | |
| Pfizer INC. | $43.66 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $39.27 | 2019 | |
| Blueprint Medicines Corporation | $34.86 | 2022-2024 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $32.24 | 2020-2021 | |
| Leo Pharma INC. | $31.45 | 2022 | |
| Covis Pharma Gmbh | $28.38 | 2019 | |
| Pharming Healthcare, INC. | $24.30 | 2021 | |
| Incyte Corporation | $23.54 | 2023 | Opzelura |
| Merck Sharp & Dohme LLC | $16.44 | 2023 | |
| Arcutis Biotherapeutics, INC. | $16.21 | 2025 | Zoryve |
| Grifols USA, LLC | $14.20 | 2023 | Xembify |
| Encore Dermatology INC. | $12.97 | 2019 | |
| Biocryst Pharmaceuticals, INC. | $11.93 | 2020 | |
| Organon LLC | $4.65 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,878.84 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzan Pae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.